DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer
The goal of this project is to improve lung cancer screening in high-risk individuals by identifying biomarkers of preclinical disease and disease risk that are measured in minimally invasive and non-invasive biospecimens. Existing biomarkers for lung cancer diagnosis as well as new biomarkers discovered specifically in this clinical setting will be examined. Biomarkers that identify individuals at highest risk for being diagnosed with lung cancer prior to the appearance of concerning symptoms could increase the utility of lung cancer surveillance and the efficiency of lung cancer chemoprevention clinical trials. Achieving these goals would improve the detection and treatment of early stage and incipient lung cancer, while restricting the risk of these procedures to those individuals who currently exhibit the early molecular warning signs of impending disease.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Apr 1, 2026 · Source: ClinicalTrials.gov
The study is underway but is not accepting new participants.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Boston University
- Interventions being studied
- Other: Biosamples from airway and blood
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- for longitudinal screening cohort
- Ages 50 to 79 years;
- Smoking status: Current or former smoker (≥10 cigarettes/day for current smokers, or ≥20 pack years for former smoker who quit 20 years ago or less)
- History of Chronic Obstructive Pulmonary Disease (COPD), emphysema, or at least one first-degree relative with a diagnosis of lung cancer;
- Willing to undergo fiberoptic bronchoscopy;
- Able to tolerate all biospecimen collection as required by protocol;
- Able to comply with standard-of-care follow-up visits, including clinical exams, diagnostic work-ups, and imaging for a maximum of four years or until diagnosis of lung cancer;
- Able to fill out Patient Lung History questionnaire;
- Willing and able to provide a written informed consent.
- Diagnosis of lung cancer prior to the current assessment (that is, patients are eligible if first lung cancer diagnosis has been recently confirmed by bronchoscopic biopsy and is leading to resection surgery, but not if this is not a first diagnosis);
- Contraindications to nasal brushing or fiberoptic bronchoscopy, including: ulcerative nasal disease, hemodynamic instability, severe obstructive airway disease (i.e., disease severity does not allow for bronchoscopic procedures), unstable cardiac or pulmonary disease, as well as other comorbidities leading to inability to protect airway, or altered level of consciousness;
- Allergies to any local anesthetic that may be used to obtain biosamples in the study;
- Weight greater than that allowable by the CT scanner.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Regents of the University of California LA (Los Angeles VA Healthcare System)Los Angeles, California
- University of California Los Angeles Medical CenterLos Angeles, California
- Naval Medical Center San DiegoSan Diego, California
- Denver Research InstituteDenver, Colorado
- Walter Reed National Military Medical CenterBethesda, Maryland
- Boston University Medical CenterBoston, Massachusetts
- Boston VA Research Institute, IncBoston, Massachusetts
- Health Research Inc. Roswell Park DivisionBuffalo, New York
- Trustees of University of Pennsylvania (Philadelphia VA Medical Center)Philadelphia, Pennsylvania
- University of PennsylvaniaPhiladelphia, Pennsylvania
- Veterans Research Foundation of PittsburghPittsburgh, Pennsylvania
- Middle Tennessee Research Institute (Vanderbilt University)Nashville, Tennessee
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 1, 2026. Always confirm current availability with the study team.